Answers are grounded in this paper and cite their sources.
Effective cancer immunotherapy requires reprogramming host immunity toward stem‐like states. However, clinical use of IL‐21 is limited by short half‐life and toxicity. Here, we develop a bio‐inspired protein nanocage platform (eQt) that encapsulates IL‐21 mRNA via high‐affinity λN‐boxB interactions during bacterial biosynthesis, enabling one‐step manufacturing and pH‐responsive endosomal release. eQt‐IL‐21 drives dendritic cell maturation, characterized by marked upregulation of CD80 and CD86, and transcriptome‐wide enrichment of MHC‐I antigen processing and presentation pathways (H2‐K1, H2‐D1, B2m, Tap2), establishing a highly stimulatory environment for T cell priming. Transcriptomic profiling of draining lymph nodes reveals that eQt‐IL‐21 preferentially diverts CD8 + T‐cell differentiation away from terminal exhaustion toward a TCF‐1 + /CCR7 + stem‐like progenitor identity, with concordant upregulation of Tcf7 , Sell (encoding CD62L), and LEF‐1 , sustaining a self‐renewing memory reservoir and long‐lived central memory T cells (Tcm). In preclinical E.G7‐OVA models, this immunological reprogramming translates into potent prophylactic efficacy and durable therapeutic remission of established tumors, without detectable systemic toxicity. This work establishes IL‐21 mRNA‐mediated immune‐cell reprogramming as a mechanistic cornerstone of durable anti‐tumor immunity, and positions the eQt nanocage as a versatile, scalable platform for precision cancer immunotherapy.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: